Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Nephrology
Crystal Arthritis
Questions discussed in this category
Do you prefer using losartan in your patients with hypertension and gout due to its uricosuric effects?
2 Answers available
Do you recommend uric acid lowering therapies for asymptomatic hyperuricemia in chronic kidney disease?
1 Answer available
If a patient who has tolerated allopurinol for a prolonged period of time is subsequently found to be positive for the HLA-B*58:01 gene, how would you manage urate-lowering therapy thereafter?
1 Answer available
Do you prefer allopurinol or febuxostat for patients with chronic kidney disease who are receiving treatment for asymptomatic hyperuricemia?
4 Answers available
How do you approach urate-lowering therapy in patients with advanced chronic kidney disease?
What doses of allopurinol do you use, and how frequently do you titrate the dose?
1 Answer available
How do you use colchicine for gout in patients with chronic kidney disease or end-stage renal disease on hemodialysis?
2 Answers available
Do you eventually stop urate-lowering therapy in gout patients with CKD who start hemodialysis?
1 Answer available
21456
14708
20755
20328
12703
14201
9645
Papers discussed in this category
The New England journal of medicine, 2018-03-29
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
Lancet, 2020 Nov 09
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Arthritis care & research, 2012-10
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.
Proceedings of the National Academy of Sciences of the United States of America, 2005 Mar 02
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.
Related Topics in Nephrology
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Genitourinary Cancers
Melanoma/Skin Cancer
Pediatric Hematology/Oncology
Prostate Cancer
Medical Oncology
Endocrine Tumors
Lymphoma